Among other findings, distinct mutational signatures, for example, SBS6, and overall mutational load, somatic mutations in PABPC1, PABPC3, and TFAM co-segregated with the resistance status, high-grade serous carcinoma subtype, or overall survival of patients. Further follow-up studies focused on utilizing the observed associations in precision oncology are now in progress in the lab.
Link to the article:https://www.life-science-alliance.org/content/5/12/e202201551
